Latest price dynamics and market overview of Eltrombopag/Eltrombopag
Eltrombopag/ Eltrombopag is a medicine designed to prevent bleeding events in adults and children 1 year and older with chronic immune thrombocytopenic purpura (ITP). ITP is a rare bleeding disorder caused primarily by insufficient numbers of platelets in the blood. In addition, eltrombopag also plays an important role in the treatment of adult patients with chronic hepatitis C who are receiving interferon therapy and in the treatment of severe aplastic anemia in adults and children at least 2 years of age. Eltrombopag is often used as an alternative when other treatments are ineffective, and in some cases it may also be used for therapeutic purposes not explicitly listed in drug guidelines, but must be used under the strict guidance of a physician.
In the domestic market, Eltrombopag is sold under the name Eltrombopag ethanolamine tablets. Common packaging specifications include 25 mg 14 tablets and 25 mg 28 tablets per box. At present, the price of each box is roughly in the range of 2,000 to 4,000 yuan, and it has been included in the reimbursement scope of Class B medical insurance. However, it should be noted that only patients who meet specific indications can enjoy medical insurance reimbursement, and patients who do not meet the conditions need to purchase it at their own expense.

Overseas markets also offer a variety of options. The original drug of eltrombopag is sold in Turkey, India and other places, and the price of each box may be around more than 1,000 yuan (the specific price may change due to exchange rate fluctuations). In addition, some countries have produced and sold generic versions of eltrombopag on the market. The ingredients of these generic drugs are basically the same as the original drugs, providing patients with more choices. At present, Bangladesh Yaopin International, Laos Lucius Pharmaceuticals, and India's NATCO Pharmaceutical Factory are all well-known generic drug manufacturers, and the price of their products may be around a few hundred yuan (also affected by the exchange rate).
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)